Dr. Kapil Juvale
Assistant Professor
Specialization : Pharmaceutical Chemistry
E
mail : kapil.juvale@nmims.edu
Phone : 022-42332000
(Extn- 2028)
Experience : 10.2 Year (Research: 2 years 6
months, Academics: 7 years 8 months)
Dr. Kapil has more than 10 years of research experience.
He has obtained PhD in Pharmaceutical
(medicinal) Chemistry from the University of Bonn, Germany in 2013. While
pursuing his PhD he also worked as a research and teaching assistant from Oct.
2009-Feb. 2013. After completion of his PhD, he continued working in the same
lab at the University of Bonn as a postdoctoral researcher. After returning to
India, from Aug. 2014-July-2016 he worked as a postdoctoral fellow at the
Indian Institute of Technology Gandhinagar. At the SPP School of Pharmacy &
Technology Management, he is working as an Assistant Professor of
Pharmaceutical Chemistry.
Interest areas:
- Design and synthesis of small molecule modulators as anticancer
agents
- Development of small molecule inhibitors of Monocarboxylate
transporters (MCT1 and MCT4) and ABC transporters involved in MDR in cancer
- Study of bacterial proteins as potential antibacterial targets
- Biochemical evaluation of small molecules
Research
- Publications – 23 (International- 23, National- 0)
- Patents- 1 Granted, 1 Published and 1 Filed
- Presentations- 14 (International- 8, National- 6)
- Research Grants: 06 (03 Completed, 03 Ongoing)
Government funded projects: 01
·Completed:
Study of monocarboxylate transporters as potential targets to exploit hypoxia
in cancer: design, synthesis and evaluation of MCT1 and MCT4 inhibitors.
Funding agency: DST-SERB, Total Outlay: ₹ 47,82,604/-
University
Seed Grant: 01
·Ongoing:Development of small
molecule inhibitors of bacterial IMP dehydrogenase as potential therapeutics
for infectious diseases. Total Outlay:₹ 1,00,000/-
Industry
Projects: 04
·Completed:Lead
Optimisation Consortium India project involving development of potential drug
candidates for Leishmaniasis sponsored by Drugs for Neglected Diseaseinitiative(DNDi),
Geneva, Switzerland. Total Outlay:₹15,12,500/-
·Completed: Collaborative research work with Drugs for Neglected
Diseases initiative (DNDi), Geneva, Switzerland for Lead Optimisation Consortium
India (LOCI) project (Part I). Total Outlay: ₹ 14,96,000/-
- Ongoing:
Collaborative research work with Drugs for Neglected Diseases initiative
(DNDi), Geneva, Switzerland for Lead Optimisation Consortium India (LOCI)
project (Part II). Total Outlay: ₹ 14,96,000/-
- Ongoing: MoU
with Drugs for Neglected Diseases initiative (DNDi) for Open synthesis Network
(OSN) involving multiple international Universities for Open-Source Drug
Discovery
Conferences/Workshops/Seminars attended-33
Academic activities
He has guided 09 M. Pharm.
students for their research projects and is currently guiding 05 M. Pharm.
Students.
Currently, four candidates are
registered for PhD under his supervision.
Awards
- Teaching excellence award
from SVKM’s NMIMS (2019).
- Indian National
Science Academy (INSA) Visiting Scientist Programme 2018-19 Award (2019).
- Postdoctoral
fellowship from IIT Gandhinagar, India (2014-2016).
- Full fellowship (€
850) to attend ‘4th FEBS special meeting, ATP-Binding Cassette (ABC)
Proteins: From Multidrug Resistance to Genetic Diseases’, Innsbruck,
Austria. (2012).
- Travel grant to attend
‘4th SFB-symposium, Transmembrane transporters in health and disease’,
Vienna, Austria. (2011).
- German academic
exchange service (DAAD) fellowship for PhD at the University of Bonn, Germany
(2009-2013).
- Fellowship for Master
of Pharmacy from AICTE, India (2005-2007).
Professional Memberships
·Association of Pharmaceutical Teachers of India (APTI) – Life
Membership (MA/LM-893)
·Registered Pharmacist at Maharashtra State Pharmacy Council.
Recent Publications
- Puri, S.; Juvale,
K.* Facile synthesis of new
N1-alkylated 1H-indazole-3-carboxamide derivatives as potential anticancer
agents: In vitro, ADMET prediction, and SAR studies. J. Mol. Struct. 2022,
1269, 133727. [I. F. 3.841]
- Kalve, S.; Hegde, N.; Juvale, K.* Applications of Nanotechnology-Based
Approaches to Overcome Multi-Drug Resistance in Cancer. Curr. Pharm. Des.
2022, DOI: 10.2174/1381612828666220401142300. [I.F. 3.116]
- Puri, S.; Patil
NS.; Juvale, K.* Investigation of some diethyl
(4-(dimethylamino)-2,5-dihydro-2,5-dioxo-1-phenyl-1H-pyrrol-3-yl)(hydroxy)methylphosphonate
derivatives for In silico pharmacokinetic profile and In vitro anticancer
activity. Chem. Pap. doi.org/10.1007/s11696-022-02329-3. [I.F. 2.097]
- Puri, S.;Juvale,
K.*Monocarboxylate transporter 1 and 4 inhibitors as potential
therapeutics for treating solid tumours: A review with structure-activity
relationship insights.J. Med. Chem.2020, 199, 112393.
[I.F. 5.572]
- Hegde, N.; Juvale,
K.*; Prabhakar, B. p-Toluenesulfonyl chloride catalysed facile
synthesis of O-benzyl-L-amino acids and their in vitro evaluation. Int. J.
Pept. Res. Ther. 2020, 26, 2129-2135. [I.F. 1.500]
- Hegde, N.; Juvale,
K.*; Prabhakar, B.*, Synthesis and in vitro evaluation of inherent
properties of l-glutamic acid based dendritic lipopeptide oligomers, J.
Pharm. Innov. 2022, 17, 228-236.
[I. F. 2.722]
- Hegde, N.; Juvale,
K.*; Prabhakar, B. *, Formulation and optimization of gefitinib-loaded
nanosuspension prepared using a newly developed dendritic lipopeptide
oligomer material. Chem. Pap. 2021, 75, 2007-2022. [I.F. 2.097]